Apr 26, 2016 at 20:00 | Source: PTI
Biotechnology firm Biocon today said its product portfolio will not be affected by an order of the Delhi High Court that prevented the company from calling its breast cancer medicine Trastuzumab as a biosimilar of Roche's Herceptin.
Apr 05, 2016 at 10:41 | Source:
It believes that Biocon's (and its partner Mylan) four potential product filings each in the US and EU would add credibility to its pipeline and bring market recognition. Emerging market monetisation is under way, but the US and EU opportunities will take at least two years, according to report.
Sep 15, 2015 at 16:45 | Source: PTI
GBR 1302, a bi-specific monoclonal antibody, is an artificial protein that is composed of fragments of two different monoclonal antibodies and consequently binds two different types of antigens.
Feb 07, 2014 at 22:27 | Source: CNBC-TV18
The Delhi High Court (HC) has thrown a wrench into plans of Biocon and Mylan to market a breast cancer drug that goes by the scientific name Trastuzumab.
Feb 04, 2014 at 09:59 | Source: PTI
The company's subsidiary Mylan Pharmaceuticals Pvt Ltd has launched the world's first trastuzumab biosimilar, which will be marketed by Mylan under the brand name Hertraz Herceptin, a company statement said.
Jan 18, 2014 at 16:21 | Source: Reuters
Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with US-based Mylan Inc.
Nov 26, 2013 at 14:42 | Source:
Biocon has received marketing authorization from the Drugs Controller General of India for its Biosimilar Trastuzumab being developed jointly with Mylan, for treatment of Her 2+ metastatic breast cancer.
Messages on Trastuzumab »


New Member



at least a dozen big pharma companies are there in the fray for trastuzumab biosimilar pie so its an open secret that there will be a big dog fight for the market share and the weakest will be edged out so expected profits can become huge losses.

12.43 PM Aug 26th


Platinum Member



Authorization Application filed by Mylan N.V. (MYL 2.9%) seeking approval of a biosimilar to Roche`s (OTCQX:RHHBY) Herceptin (trastuzumab). Mylan co-developed the product candidate with Indian biopharma firm Biocon (OTC:BCNQY).

9.18 PM Aug 25th

Wire News

Platinum Member


News Now  

European Medicines Agency (EMA) has accepted for review Mylan's application to market biosimilar Trastuzumab, co-developed with Biocon, that is used to treat certain breast and gastric cancers.

8.46 PM Aug 25th


Gold Member



Results were good.Unexpectedly better than I anticipated. Biosimilar Trastuzumab (Herceptin, Mylan alliance) commences Phase III trials in India. This seems to be a new drug which I did not know this either. It appears,they have lot more valuable molecule which are yet to be valued. KMS is silent

2.03 PM Apr 27th 2012


Platinum Member


Biocon Rajiv malik -Mylan NV " Turning first to our biosimilars portfolio, we are pleased to report that we remain on track to file trastuzumab, pegfilgrastim, and glargine to U.S. FDA and European Medical Agency in 2016

3.21 AM Oct 2nd


New Member



`s application for biosimilar Trastuzumab. Remember, its` Biomagic at work!!

11.21 PM Sep 26th

Explore Moneycontrol

Copyright © Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of is prohibited.